Food Is Life Is Love Is Food

Imagine being the restaurant critic of The New York Times, which is tantamount to being a professional eater. There you are in one of the world’s largest and most opulent cities, famous for (among other things) its abundance of fine dining establishments, with not only the opportunity but the obligation to eat, eat, eat. Actually, we don’t need to imagine the experience, because Frank Bruni, author of Born Round: The Secret History of a Full-Time Eater, has described the dilemma in 354-page detail.

During his five years as “one of the most loved and hated tastemakers in the New York restaurant world,” it was Bruni’s profession to dine not only in his newspaper’s native city but all over the USA. This duty coincided with his lifelong struggle against obesity.

Several Childhood Obesity News posts have mentioned the particular difficulty that many people experience in getting through holidays, when family gatherings are fraught with the emotional obligation to eat everything that isn’t nailed down. For chubby and perpetually hungry little Frank, whose mother and grandmother both existed with one purpose — to cook massive, calorie-laden meals — this was every day of his young life.

Even when his mom had misgivings and tried to impose some limits, it was impossible to avoid constant clashes with the overwhelming emotional equation: If you don’t love Grandma’s food, you don’t love Grandma. Eventually, his mom gave up and, just like Grandma, “cooked with a ferocity.”

Growing up — and out

To complicate matters further, little Frank was a naturally inactive child. If reading books could burn calories, he would have been fine. Sadly, that was not the way of things. Heading into his teens, Bruni got into swimming, but basically remained a fat kid. Then there was the considerable matter of realizing that he was gay. All the while, and rivaling his massive love for his family, the abiding passion of his young life was food.

As a college freshman, he was already into diet pills, laxatives, and bulimia. Embarking on his journalistic career, the young man weighed well over 250 pounds. Eventually, a friend hooked him up with her personal trainer, and change began to occur. By the time he became a restaurant critic, he had mastered the technique of portion control.

Reviewer Dominique Browning notes that this life story is not only told with humor, but is “embarrassingly, inspiringly honest” and adds,

I could feel the profound pleasure he took in his work — both the dining and the writing. No matter whether he was covering slow food or fast, fancy or fraught or both, he seemed to want to invite everyone to the table with him…

Another reviewer, George Ilsley, seems to have approached this autobiography from a strictly psychological angle, saying,

Even when others like him and admire the way he looks, Bruni still seems to feel fundamentally unattractive. In my opinion, he never reached the core of that false core belief, and the societal programming that drove it, like poison, into the depth of his soul.

Yet another description characterizes Born Round as a “heartbreaking and hilarious account of how he learned to love food just enough,” and opines that the book “will speak to every hungry hedonist who has ever had to rein in an appetite to avoid letting out a waistband.”

Your responses and feedback are welcome!

Source: “Weight Watcher,” NYTimes.com, 08/19/09
Source: “Born Round: The Secret History of a Full-Time Eater,” Goodreads.com, undated
Source: “Born Round: A Story of Family, Food and a Ferocious Appetite,” Goodreads.com, 09/18/17
Image: Book cover/Public Domain

Fat and Happy… Not

Just for grins, compare the latest statistics on the world’s happiest countries and the most obese countries. Recently, writer Frank Jacobs noted,

As usual, the country ranking in the annual World Happiness Report is topped by Nordic countries.

According to the Gallup World Poll, they are Finland, Iceland, Sweden, and Denmark. How do those felicitous lands stack up against the most obese countries? There are different ways to compare the statistics, mainly by “mean BMI of both sexes.” But BMI has been discredited and while most places still go by it, the more advanced have switched to other metrics, like the combined male and female obesity rate.

Still, according to the currently accepted standard of measurement, in the four happiest countries, the percentage of obese adults looks pretty good with these figures: Finland 22.2%, Iceland 21.9%, Sweden 20.6%, Denmark 19.7%.

In contrast: When measured by the combined obesity rates of both sexes, the “percentage of obese adults,” in the world’s direly affected countries is as high as 61% (Nauru), 55.0% (Cook Islands), 55.3% (Palau) and 52.9% (Marshall Islands).

Big picture, little picture

So, on a global scale, and for many reasons, the happiest humans and the most overweight humans constitute very different populations. However, narrowing the assessment down to a certain population, the professional comedians of the world look pretty darn euphoric. Of course, laughter is not always synonymous with happiness, as they will be the first to attest.

An entire sub-genre of professional comedians have suffered from the belief that if they give up their addictions — whether to alcohol, downers, uppers, food, or whatever — they will no longer be able to either mentally generate material, or perform in front of crowds. One way they handle this almost ubiquitous problem is by organizing for mutual help toward the practice of self-help.

In Atlanta, for instance, an outfit called Stand Up 4 Recovery was founded by comic Ricky Satori who, now more than 10 years sober, told reporter Kenny Murry about the early stage of his recovery process:

I could be onstage, I could say something confessional about my drug use … and I could follow it up with a punchline and experience the therapeutic value of not being suffocated with secrecy. Also, if it came up in court, I could say, “I was just kidding!”

This innovator is registered as a Certified Addiction Recovery Empowerment Specialist, and is qualified to train people to use naloxone (which saves users who overdose on opiates). He runs a mobile comedy club that honors individuals celebrating their Soberversaries by giving them support, encouragement, and even gifts. He also created a special array of “mocktails” for customers to enjoy. Collaborators include comedian/actor Taylor Neely, who also hosts the podcast “Sober Boyz.”

Father of them all

Another example of this type of service organization is the Lenny Bruce Memorial Foundation, founded by the legendary comedian’s daughter Kitty Bruce. It provides scholarships for sober living programs aligned with the foundation’s core values, which include education on how to survive daily life without using substances; focus on positivity and spirituality; self-esteem building; volunteer work; and enjoyable sober experiences.

Your responses and feedback are welcome!

Source: “Mapped: The highs and lows of the world’s happiness landscape,” BigThink.com, 05/07/24
Source: “Most Obese Countries 2024,” WorldPopulationReview.com, undated
Source: “Atlanta comedians ‘Stand Up’ for addiction and mental health recovery awareness,” WABE.org, 01/23/24
Source: “The Lenny Bruce Memorial Foundation,” LennyBruce.org, undated
Image by Stand Up 4 Recovery

Dicey Substances and Treacherous Fakes, Part 2

This post continues a recent post, and this one is as disturbing as the other. Last month, Registered Dietitian Catherine Rall told Healthline.com,

Any time you’re taking an unregulated drug, you’re taking a huge risk since it could literally contain anything. The best case scenario, outside of the unlikely idea that someone is selling Ozempic at below-market prices, is that you get an inert placebo. There’s also a huge risk that you’re putting something dangerous into your body.

The article also notes the warning voiced by Registered Nurse Nancy Mitchell, that the customer risks receiving harmful toxins, including heavy metals:

Every year, hundreds of people show up in the ER with severe allergic reactions or lead poisoning that they acquired from some unknown generic source.

Of course, the World Health Organization warns the public about counterfeit websites, but given the high prices of bona fide pharmaceuticals, the widespread shortages, and the human tendency to hope for and believe in the impossible, caution is unlikely to be observed. Face it, most of us are nice people who can’t really believe that someone would sell us fake medicine that might be worse than useless.

Potential users are urged to verify the legitimacy of online pharmacies, but who knows how to do that?

And to be realistic, do people really care? The perils that may result from giving away any personal information online are just beginning to register in the average person’s consciousness. The world is full of endearing, lovely people who trust strangers enough to willingly fill out social media “get to know me” quizzes. Clever criminals collect all kinds of facts, and know more than anyone needs to about a person’s first pet, the color of their first car, and who their prom date was in 1980.

Be afraid… Be very afraid

A VanityFair.com piece by Katherine Eban reinforces all the caveats:

Under US law, drugs are supposed to travel seamlessly from a manufacturer’s loading dock to a distributor’s pristine warehouse to a pharmacy shelf through a protected chain of companies that follow strict requirements for handling medications and documenting sales.

“On the contrary,” says her story which traces the meticulous investigation into a particularly odious and huge batch of thousands of fake Ozempic pens that were dumped on the market last year, and also goes into the matter of drugs that are real enough, but “diverted” from the legitimate channels. Eban writes,

The drugs may well be authentic, but they might also be expired, improperly stored, or contaminated. Under FDA rules, diverted drugs are considered adulterated and not fit for human consumption, because their safety and quality cannot be guaranteed.

The globe is populated with criminals who “have been learning as they go how to breach America’s defenses in order to sell their counterfeit medicine in the most expensive, and lucrative, market in the world.” This market includes the proprietors of some weight-loss spas whose practices are unsavory, to say the least.

The Illinois Poison Center’s medical director, Michael Wahl, M.D., told the reporter that many patients have injected insulin disguised as Ozempic — which for non-diabetics can be seriously life-threatening, because if the body’s glucose level is too low for too long, irreversible brain damage may result.

In addition to the outright fakes and the stolen or “diverted” goods, there is the additional problem of legal but under-scrutinized and possibly untested substances. There are loopholes, under certain conditions of unavailability, that allow licensed “compounders” to manufacture drugs. Their ingredients are sometimes obtained from sources that cannot be described as either impeccable or acceptable:

Not every pharmacy compounder is equal in adherence to the law… The result has been a quality control disaster.

It looks as if people need to seriously ask themselves whether losing some pounds of flesh can be worth the price of losing an organ or even a life, especially when other methods, though difficult, are possible.

Your responses and feedback are welcome!

Source: “WHO Issues Global Warning About Fake Ozempic Being Sold Online,” Healthline.com, 06/24/24
Source: “Why Counterfeit Ozempic Is a Global-Growth Industry,” VanityFair.com, June 2024
Image by Richard Patterson/Attribution 2.0 Generic

Dicey Substances and Treacherous Fakes, Part 1

Both traditional news outlets and newer social media platforms are bulging at the seams with advertisements and celebrity endorsements that lead to ever-increasing sales of bogus anti-obesity drugs, as well as horrendously complicated and expensive problems for law enforcement agencies at every level. Unlicensed pharmacies that operate online are happy to fulfill the demand for semaglutide.

Problem is, consumers tend to receive some totally different substance; or the real stuff but it’s contaminated with something else; or it’s the real stuff but less than the advertised amount, or — and apparently this has actually happened — the genuine item, but a larger dose than was specified in the advertising. Whatever a person injects, to receive close to 40% more of it than they intended to take is a serious drawback.

Pharmacovigilance is called for

Plenty of bargain-priced or even full-priced stuff is on the market, except it turns out to be ineffective, dangerous, falsified, unregistered, misbranded, unapproved, or some other kind of bogus. And/or dangerous. Health-wise, the best-case scenario is the simple non-delivery scam, which one news source implied can at least do no one any harm, other than losing some money.

But even that consolation is false. Some of these crooks who never intended to send any goods want not only the money, but the customer’s credit card number and additional personal information for other nefarious purposes. Meanwhile, shipments actually sent out have caused an alarming increase in emergency calls to poison control centers.

Literally hundreds of websites are selling purported Ozempic, Wegovy, Mounjaro, and other fakes. For CBC news, Sheena Goodyear reported that last year alone, one security firm managed to get more than 250 of these criminal sites banished from cyberspace. But the crooks, and the tech wizards who use their powers for evil, are standing by ready to replace each deleted site with another one, or several more.

A different cybersecurity firm got 1,600 fake pharmacies removed from the web last year, at least a couple hundred of which had been peddling spurious GLP-1 concoctions. Here is an interesting sentence:

BrandShield said it had the fake pharmacy websites taken down by collecting evidence against them, and submitting that to the service providers hosting the sites.

Sadly, there is no guarantee that the service providers are conscientious and honest citizens, either. The ISPs that host advertising by irresponsible and greedy criminals might be equally craven, avaricious, and unprincipled. In these cases, international law enforcement agencies must step in, and matters become truly complicated. Some countries simply are not interested in playing nice, or being good global neighbors.

Goodyear quoted health law expert Lawrence Gostin, who has been tracking this sort of activity for at least a decade: “Few people understand that the international market in counterfeit drugs is massive.” He also emphasizes that if a person does order weight-loss injections from an online source, they’d better hope the substance that arrives is nothing worse than normal saline.

Sadly, the web is not the only source of danger. Many Americans have been offered stolen, “diverted,” or fake meds in unconventional locations, like a shopping center parking lot, by someone selling from the trunk of a car. Or perhaps in a college dorm.

And even, as journalist Katherine Eban reported for Vanity Fair, at the annual convention of the Obesity Action Coalition, where a dicey character, who was not even a registered attendee, sidled up to the medical professionals in a “stalker-ish” manner. Eban wrote:

Approaching doctors at the conference, he held up a crumpled piece of notebook paper with his contact information and his product list. The sales pitch was simple: [his company] could provide automated refills for “Ozempic, Saxenda, Mounjaro, etc.” at roughly one third of the going US price.

Shame and blame

Another factor that drives some people to online pharmacies is reluctance to face their own doctors, because correctly or not, they perceive bias or criticism coming from that direction. They are afraid their own physician will just plain refuse. Or the doctor might say that the newest weight-loss drug is unavailable — which the patient “knows” to be untrue, because obviously there it is, all over the World Wide Web.

The scary thing about this is, anyone who is taking even the genuine GLP-1 meds needs to be carefully monitored because they may wind up with stomach paralysis, intestinal blockage, or pancreatitis. And once a plethora of unknown substances enters the picture, anything can happen.

Those drugs should never be sold without a legitimate prescription from trained medic who has actually examined the patient — just as no patient should trust any alleged drug that has not been prescribed by a medical professional. Then, since these drugs come loaded into self-injection devices, there is the non-trivial fact that the needles might not be sterile.

(To be continued…)

Your responses and feedback are welcome!

Source: “Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases,” JAMANetwork.com, 08/02/24
Source: “Hundreds of websites are selling fake Ozempic, says company,” CBC.ca, 04/19/24
Source: “Why Counterfeit Ozempic Is a Global-Growth Industry,” VanityFair.com, June 2024
Image by danieljordahl/Attribution 2.0 Generic

Are Important Questions Being Asked?

A ScientificAmerican.com article published last year was not alone in raising a valid point or two. Writer McKenzie Prillaman speculated on the validity of welcoming the GLP-1 drugs as some sort of medical messiah:

Another unknown is who will respond to these drugs — and who won’t. It’s too early to tell now, but the drugs seem to be less effective for weight loss in people with type 2 diabetes than in those without. Conditions such as fatty liver disease and having fat around the organs, known as visceral body fat, might also affect how people respond to different drugs.

Aspersions have been cast by, among others, Matthias Tschöp, a German physician and scientist. Who will respond to these drugs and who won’t? Hesitancy and caution bring up other questions that many professionals feel really must be answered first: exactly who needs to respond to these drugs, and why do they need to? Because there is still doubt in some minds about whether “obesity” is such an enormous problem after all.

The link between excess weight and health is not proven to the satisfaction of everyone. Why?

One study found that nearly 30% of people who are considered obese are metabolically healthy. Another showed that other health problems tend to be a better predictor of someone’s risk of death than is weight, demonstrating the need to consider factors other than weight when judging health.

And indeed, it is possible that a person whose eyelashes fall out or whose fingernails show grooves is more likely to develop some fatal condition than an obese person is. Biology and medicine are two fields that never run out of surprises, so who knows?

Keeping up, or being led by the nose?

Then along comes another expert, like biologist Timo Müller, to point out that times have changed, especially after semaglutide arrived on the scene. Previously, using pharmacology to reduce weight by more than 10% had proven to be unsafe for patients’ overall physical well-being.

Still, these newer drugs held out the promise of performing other services, like improving cardiovascular health. Tirzepatide increased the “wow” factor even more, with its ability to rival the effectiveness of bariatric surgery by enabling the loss of, in some cases, 20% of the patient’s body weight.

And yet… did that individual really need to be changed into four-fifths of their former self? Misgivings were expressed by psychologist Sarah Nutter, whose main areas of interest are body image and weight stigma. The particular concern here is that patients are letting themselves in for a lot of misery, what with nausea and vomiting and so forth — “to escape weight stigma, rather than to serve a true health need.” There is also concern that people are overly influenced by reports from celebrities, and by news stories aiming to convince folks that once they lose weight, all their pesky life problems will disappear.

Celebration or desperation?

There is a feeling in some quarters that the public is being brainwashed into paying well over $1,000 a month to solve what just possibly might be a non-problem. Perhaps these individuals could be better served by spending that money on psychological counseling, or any kind of therapy, rather than ingesting substances that may not offer permanent health, and indeed might cause actual harm.

The insurance companies that balk at dishing out the dollars may not be solely motivated by reluctance to part with the cash. Their reluctance to pay for “vanity drugs” might even indicate genuine concern for the patients’ well-being. After all, stranger things have happened. But then, the other side comes along with multiple proofs of the enormous damage that can be caused by untrammeled obesity.

When a large number of 20-year studies about GLP-1 drugs and their close relatives have been completed, we can rest assured that someone will always say, “That is all well and good, but what about the 30-year studies? We need those.” It might be that some answers will never satisfy.

Your responses and feedback are welcome!

Source: “Breakthrough’ Obesity Drugs Are Effective but Raise Questions,” ScientificAmerican.com, 01/10/23
Image by airpix/Attribution 2.0 Generic

The GLP-1 Drugs — More Questions and Issues

As mentioned in a previous post, there are a lot of things nobody knows very much about. The GLP-1 drugs have been around for a while, although mainly as a diabetes treatment. As weight-loss drugs, however, they are relatively new and untried. Just as with any discovery that comes down the road, questions arise.

Which patients could or will be harmed? Which sufferers will receive the most benefit? How much will they pay? How much would they be willing to pay if they had a lot more money to start with? Where will the funds come from instead? How about the pharmacology? What other drugs does this new thing clash with, causing iatrogenic disaster and/or scandal? Can the team that wrote a particular paper continue to do meaningful work in this area?

Bloomberg journalist Lisa Jarvis raised several questions, such as:

Why do some people on GLP-1s […] experience a total body transformation, while others lose only modest amounts of weight — or nothing at all?

Is there a way to figure out who needs these drugs to avoid a heart attack or diabetes, and who is perfectly healthy in their larger body?

Is constant therapy sustainable — or even required?

Jarvis states, “Some 44% of people taking Wegovy report nausea, and nearly a third experienced diarrhea.” People know this is going on but give it a chance anyway, and a very large number of them seem to stay with it despite the discomfort. The sickness seems to be a feature, not a bug. If that’s what is required, people seem willing to put up with it.

Time out?

Apparently, huge numbers of users want to know if they may self-prescribe a break from their medication regime. The professional consensus on that is, “No.” Resistance understandably crops up a lot, around holiday times. Reportedly, someone who stops their meds abruptly will become ravenously hungry, and prone to eat an enormous amount of barbecued ribs and hot fudge sundaes.

If somebody does take a break, the next big question seems to be whether they should pick up again with the dosage they previously used, or whether they need to fall back to a smaller dose and then crank it up again. Journalist Ross Wollen wrote,

It takes the body some time to adjust to these potent medications, and those infamous gastrointestinal side effects tend to be at their very worst in the first few days of a new higher dose. With longer pauses, the worry is that your body might lose some of the tolerance that originally allowed you to step up your dosage.

Starting over with the high dose that was typical before the break “could be more than your body is ready to handle, resulting in extremely uncomfortable side effects.” Medical professionals prefer to stay on the side of caution, recommending a wary approach before ramping up. Apparently this is not yet verified by published studies — but it is the tactic preferred by doctors, who definitely want to be consulted, rather than see patients improvise their own unauthorized medication calendars.

Patients who go rogue with their dosage schedules might meet with surprises. They may not be aware that it takes at least a week for the last dose to clear their system. If someone wants to devour a big meal on a certain day, careful planning is needed. Even then, the mere ability to chew and swallow a large amount is no guarantee that the organs farther down the line will cooperate. What polite society calls “ugly gastrointestinal side effects” may occur.

Your responses and feedback are welcome!

Source: “Do You Really Have to Take Wegovy Forever?,” WashingtonPost.com, 10/19/23
Source: “Is It Okay to Skip an Ozempic Shot Now and Then?,” EverydayHealth.com, 11/15/23
Image by Camdiluv/Attribution-ShareAlike 2.0

With GLP-1 Drugs, There Will Be Questions — Continued

About the GLP-1 drugs, there are currently more questions than answers, and one of them is, are the most important questions even being asked?

New England Journal of Medicine produces a podcast called “Intention to Treat.” In one episode, host Rachel Gotbaum discusses with guests the prescribing of such pharmaceuticals to children. Dr. Ali Ibrahim expresses concern about overprescription, especially when prices eventually go down and the genre becomes more affordable. Given that many doctors do not have special expertise in nutrition or exercise physiology, “[…] it is very easy for someone who’s not trained in these two things to quickly jump to the medications.”

This, he feels, is probably not the best course for the patient, because “lifestyle should always be at the center… We need to create a tailored plan for every single patient.” Dr. Ibrahim also has a specific concern about general quality of life, and a reluctance to contribute to mental health problems like feelings of deprivation and pointlessness. For most patients, “having a meal is the best part of their day. This is what keeps them going. And now I’m putting them on a medication that is making that less enjoyable. And I do not want to take that away from them.”

Speaking of teens who have lost a lot of weight due to bariatric surgery, Dr. Tamara Hannon mentions a factor “that is quite worrisome… and that’s the use of other substances — alcoholism, substance abuse kind of replacing food, in a way.”

Notorious teens

Not too long ago, in the autumn of 2022, a pharmaceutical company astonished an Obesity Week conference audience by describing “a promising anti-obesity medication in teenagers, a group that is notoriously resistant to such treatment”:

The results astonished researchers: a weekly injection for almost 16 months, along with some lifestyle changes, reduced body weight by at least 20% in more than one-third of the participants.

Results like this shed new light on the question of whether obesity is a disease — that is, a condition that at least some people have no power over, and unquestionably need medical help to fix. And here is some bad news: “[E]vidence is growing that most people’s bodies have a natural size that can be hard to change.” This is a shocker. Remember the dreaded Set Point Theory?

One big question facing researchers now is whether people will need to take these medications for life to maintain their weight. A subset of clinical-trial participants who ceased taking semaglutide and stopped the study’s lifestyle interventions regained about two-thirds of their lost weight after one year.

The future

Something that may or may not turn out to work is a drug called 2,4-dinitrophenol, or DNP. As a weight-loss aid, it is described as highly effective but potentially deadly. It makes use of a process called mitochondrial uncoupling, which HU6, a drug in development, might be able to accomplish without causing the user to overheat.

It is said to bring about “fat-specific weight loss, preservation of muscle mass, reduction of liver and visceral fat, improved glycemic control and reductions in oxidative stress and inflammation.” A BioSpace.com article quotes Jayson Dallas, CEO of the company responsible:

HU6 increases resting energy consumption by about 30% at its highest dose, “and it does that 24/7… You’re essentially burning 30% more energy than you otherwise would, all day, and therefore you’re burning an extra 3600 to 4000 calories a week in the background.

That sounds kind of like being cooked from the inside. The executive recognizes the possible shortcomings and the danger it would present:

The more you shock your body, the more it goes into panic mode, and when you’re losing 30% of your body weight in 12 weeks, that’s a crisis metabolically.

HU6 reportedly helps patients lose three to four pounds per month with “no plateau,” which sounds pretty extreme, and of course could not be literally true, or the body would eventually just dissolve away into nothingness. But perhaps with the right amount of tinkering, this substance will find its heat problem solved, and leave all the GLP-1 drugs in the shade.

Your responses and feedback are welcome!

Source: “Treating Obesity in Kids — ITT Episode 31,” NEJM.org, 06/05/24
Source: “‘Breakthrough’ Obesity Drugs Are Effective but Raise Questions,” ScientificAmerican.com, 01/10/23
Source: “Beyond GLP-1s: The Next Obesity Treatments,” BioSpace.com, 07/08/24
Image by Mary/Attribution-ShareAlike 2.0 Generic

With GLP-1 Drugs, There Will Be Questions

As mentioned in a previous post, there are a lot of things about which nobody knows very much. The GLP-1 drugs have been around for a while, although mainly as a diabetes treatment. As weight-loss aids, however, they are relatively new and untried. When any discovery comes along, questions arise.

Which patients will or could be harmed? Which sufferers will receive the most benefit? Scientific American said,

Another unknown is who will respond to these drugs — and who won’t. It’s too early to tell now, but the drugs seem to be less effective for weight loss in people with type 2 diabetes than in those without. Conditions such as fatty liver disease and having fat around the organs, known as visceral body fat, might also affect how people respond to different drugs…

How much will the patients pay? How much would they be willing to pay if they had a lot more money to start with? Where will the funds come from instead? Can the team that wrote a particular paper continue to do meaningful work in this area? How about the pharmacology? What other drugs does this new thing clash with, causing an iatrogenic disaster?

Bloomberg journalist Lisa Jarvis raised several questions, such as:

[…] Why do some people on GLP-1s […] experience a total body transformation, while others lose only modest amounts of weight — or nothing at all?

[…] Is there a way to figure out who needs these drugs to avoid a heart attack or diabetes, and who is perfectly healthy in their larger body?

[…] Is constant therapy sustainable — or even required?

Jarvis states, “Some 44% of people taking Wegovy report nausea, and nearly a third experienced diarrhea.” People know this going in, and give it a chance anyway, and a very large number of them seem to stick with it despite the discomfort. The sickness seems to be a feature, not a bug. If that is what it takes to stop people from overeating, they seem willing to put up with it. But is it a life sentence? Or at least, will the necessity for periodic injections segue into discovery of how to make wider and more efficient use of alternate routes?

Time out?

Apparently, huge numbers of users want to know if they may self-prescribe a break from their medication regime. (The professional consensus on that is, “No.” But a certain number will do it anyway.) Resistance understandably crops up a lot, around holiday times. And reportedly, someone who stops their meds abruptly will become ravenously hungry, and prone to eat an enormous amount of barbecued ribs and hot fudge sundaes.

If a user does take a break, the next big issue seems to be whether they should pick up again with the dosage they previously used, or whether they need to fall back to a smaller dose and then crank it up again. Journalist Ross Woolen wrote,

It takes the body some time to adjust to these potent medications, and those infamous gastrointestinal side effects tend to be at their very worst in the first few days of a new higher dose. With longer pauses, the worry is that your body might lose some of the tolerance that originally allowed you to step up your dosage.

Starting over with the high dose that was typical before the break “could be more than your body is ready to handle, resulting in extremely uncomfortable side effects.” Medical professionals prefer to play it conservatively, recommending a cautious approach before escalating. This is not yet backed up by published studies apparently, but is the tactic preferred by doctors, who definitely prefer to be consulted rather than see patients tailoring their own medication schedules.

Patients who invent unauthorized dosage schedules might encounter surprises. They may not be aware that it takes at least a week for the last dose to clear their system. If someone wants to devour a big meal on a certain day, careful planning is needed. Even though they might have an enormous appetite, the mere ability to chew and swallow a large amount is no guarantee that the organs farther down the line will cooperate. There may still be “ugly gastrointestinal side effects.”

Your responses and feedback are welcome!

Source: “‘Breakthrough’ Obesity Drugs Are Effective but Raise Questions,” ScientificAmerican.com. 01/10/23
Source: “Do You Really Have to Take Wegovy Forever?,” WashingtonPost.com, 10/19/23
Source: “Is It Okay to Skip an Ozempic Shot Now and Then?,” EverydayHealth.com, 11/15/23
Image by Holly Lay/Attribution 2.0 Generic

The GLP-1 Meds vs. Muscle, Continued

The loss of muscle mass that inevitably accompanies fat loss is a hazard to teens who are prescribed a GLP-1 drug, as we have seen. Not surprisingly, seniors are also at risk.

According to the governmental branch that keeps track of these things, a leading cause of death among that age group is falling, and falling may be caused by what? Exactly — the loss of muscle mass, which holds the bones together and enables them to either move or remain still, as the situation requires.

That is on the physical side, and on the psychological/emotional side, older patients who successfully lost weight might feel they have been given a second chance, a new lease on life. Such a person might be tempted to try a dangerous or downright foolish activity, without the muscular ability to carry it through successfully.

When Madison Muller’s piece was written last year, it included these words about a trial of semaglutide that included 140 participants: “On average, participants lost about 15 pounds of lean muscle and 23 pounds of fat during the 68-week trial.” The mean age of those patients, however, was 52, which is pretty young for this era of ever-aging populations, and so it might reasonably be expected that older patients would not even do that well.

Meanwhile, Eli Lilly is developing the very inelegantly-named bimagrumab, which holds some promise to be a muscle-mass preserver, to be used in combination with the company’s tirzepatide.

Cautious optimism only

When clinical researcher Dr. Donna H. Ryan wrote about next-generation anti-obesity medications, her Introduction implied that in general, the ones in development were not quite meeting expectations:

The goal of medically supervised weight loss has been modest, or at most, moderate, weight loss — principally because that is all that could be regularly achieved.

At the same time, she named two “interesting and unique” examples as “generating much interest.” Specifically, they are the GLP-1 dual agonist tirzepatide (weekly injection) and the “new agent with a unique mechanism of action,” bimagrumab, which not only eliminates fat mass but preserves and promotes the gain of lean mass.

Apparently, although only needed once a month, it must be administered intravenously in the hospital. Still, bimagrumab “gives the first evidence that we might succeed in targeting improved quality of weight loss for our patients.” In the “Conclusions” section of the piece, Dr. Ryan waxes poetic:

Of course, it would be better to live in a world where healthy eating and active living were the default behaviors and where those behaviors were reinforced in a world without undue emotional and financial stress. All of us need to work toward creating that world…

We are, however, not quite there yet. According to one report, although bimagrumab can increase muscle weight in mice and cultured myotubes, it has no demonstrable effect on increasing muscle strength:

On this background, a large controlled study was performed with 251 patients randomized to receiving monthly bimagrumab or placebo for 52 weeks. No change in the study’s primary end-point was noted compared to placebo; all enrolled patients continued to worsen with further deterioration in quantitative muscle strength testing, with more falls, and worsening swallowing.

The Canadian company 35Pharma developed a molecule called HS235 which sounds very promising. Last October, they announced that lab mice who only got tirzepatide “lost 46 percent of their fat mass.” The ones who received a tirzepatide and HS235 combo “lost 64 percent of their fat mass” without, apparently, losing any muscle mass.

Journalist Sumi Sukanya Dutta explained the importance of not losing too much weight, too fast:

Good muscle mass is vital for resting metabolic rate, which, simply put, means the ability of the body to burn calories even while resting… Less muscle is lost with less aggressive weight loss programmes.

Your responses and feedback are welcome!

Source: “Weight-loss drugs pose risks for people over 65, experts say,” BusinessMirror.com, 10/21/23
Source: “Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?,” NIH.gov, 09/30/21
Source: “Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders,” ScienceDirect.com, 2023
Source: “Move over semaglutide, new drug on the horizon promises to melt only fat, not muscle,” ThePrint.in/health, 10/22/23
Image by GreenFlames09/ATTRIBUTION 2.0 GENERIC

The GLP-1 Meds vs. Muscle

Muscle mass is a large and rather frightening issue, overall. As previously mentioned, any legitimate weight-loss regime must aim to shed the greatest possible amount of fat, while retaining the largest possible amount of muscle, because a healthy balance of the two is paramount — and as it turns out, very difficult to achieve.

The whole point of these meds is to help the patient eat less, which in itself could be a problem if it leads to an insufficient intake of protein. To maintain and build muscle, several macronutrients from other sources are also important:

Alongside resistance training, research suggests consuming 1.4–2 grams (g) of protein for each kilogram of body weight per day to maximize muscle building. However, it’s important to consume a well-balanced diet that includes healthy carbohydrates and fats.

The Healthline article quoted above, like many similar guides, goes on to recommend a plethora of excellent protein sources.

The necessary

On the most practical level, long-term weight loss is almost impossible to maintain unless dietary caution is accompanied by plenty of exercise for the muscles. In addition, the older a person becomes, the more the body must struggle to maintain muscle while shedding fat. Some doctors who prescribe the GLP-1 meds have become alarmed by the disproportionate loss of muscle mass in their older patients.

In any case, it is unwise to measure only overall weight loss, without distinguishing between fat and muscle — which is the strongest objection to the near-universal use of Body Mass Index as the official measurement tool.

Among other outcomes, this ongoing source of unease within the community has led to the creation of a new category, of which plenty of people are members:

In simple terms, ‘skinny fat’ refers to someone who looks fit and healthy from the outside, but who is actually carrying excess visceral fat internally… But the reality is that this hidden belly fat can lead to some serious health problems.

The medical term for this is Metabolically Obese Normal Weight (MONW).

“Intention to Treat” is a podcast produced by the New England Journal of Medicine, hosted by Rachel Gotbaum, and one of this summer’s episodes discussed the recent approval of GLP-1 drugs for children. Guest Dr. Ali Ibrahim first establishes that with or without medication, any kind of slimming endeavor will inevitably involve the loss of not only fat tissue, but lean muscle mass as well.

That loss cannot be eliminated, but it can be limited, maybe… probably… eventually. This is especially important when the patient is a child or teen, because “we’re putting them through a catabolic state, a state of breakdown, whether it’s adipose-tissue breakdown, whether it’s lean-muscle breakdown…”

Dr. Ibrahim is one of many who ask some version of the question, “What is going to happen to them in the future, especially if they continue being on this medication for decades?” He goes on to say,

These are chronic medications. They’re not meant for use for short-term use. Once we start them, for most people, they will have to continue on these medications for the rest of their lives.

Your responses and feedback are welcome!

Source: “26 Foods to Eat to Gain Muscle,” Healthline.com, 02/15/24
Source: “What is skinny fat? Causes, risks and how to fix it,” GoodTo.com, 07/20/22
Source: “Treating Obesity in Kids — ITT Episode 31,” NEJM.org, 06/05/24
Image by Aidan Jones/ATTRIBUTION-SHAREALIKE 2.0 GENERIC

FAQs and Media Requests: Click here…

Profiles: Kids Struggling with Weight

Profiles: Kids Struggling with Obesity top bottom

The Book

OVERWEIGHT: What Kids Say explores the obesity problem from the often-overlooked perspective of children struggling with being overweight.

About Dr. Robert A. Pretlow

Dr. Robert A. Pretlow is a pediatrician and childhood obesity specialist. He has been researching and spreading awareness on the childhood obesity epidemic in the US for more than a decade.
You can contact Dr. Pretlow at:

Presentations

Dr. Pretlow’s invited presentation at the American Society of Animal Science 2020 Conference
What’s Causing Obesity in Companion Animals and What Can We Do About It

Dr. Pretlow’s invited presentation at the World Obesity Federation 2019 Conference:
Food/Eating Addiction and the Displacement Mechanism

Dr. Pretlow’s Multi-Center Clinical Trial Kick-off Speech 2018:
Obesity: Tackling the Root Cause

Dr. Pretlow’s 2017 Workshop on
Treatment of Obesity Using the Addiction Model

Dr. Pretlow’s invited presentation for
TEC and UNC 2016

Dr. Pretlow’s invited presentation at the 2015 Obesity Summit in London, UK.

Dr. Pretlow’s invited keynote at the 2014 European Childhood Obesity Group Congress in Salzburg, Austria.

Dr. Pretlow’s presentation at the 2013 European Congress on Obesity in Liverpool, UK.

Dr. Pretlow’s presentation at the 2011 International Conference on Childhood Obesity in Lisbon, Portugal.

Dr. Pretlow’s presentation at the 2010 Uniting Against Childhood Obesity Conference in Houston, TX.

Food & Health Resources